Literature DB >> 14638514

Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice.

Javier Capilla1, Carolina Serena, F Javier Pastor, Montserrat Ortoneda, Josep Guarro.   

Abstract

We have evaluated the efficacy of voriconazole (VRC) in a murine model of systemic infection by Scedosporium apiospermum. The survival of mice treated with VRC at 5, 20, or 40 mg/kg/day was greater than that of the control group (P< or =0.0009). VRC reduced the tissue burden in the spleen and brain (P<0.001 in both organs) in comparison with that of the control group.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14638514      PMCID： PMC296198          DOI： 10.1128/AAC.47.12.3976-3978.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy.

Authors:  P Muñoz; M Marín; P Tornero; P Martín Rabadán; M Rodríguez-Creixéms; E Bouza
Journal:  Clin Infect Dis       Date:  2000-12       Impact factor: 9.079

2.  In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.

Authors:  Joseph Meletiadis; Jacques F G M Meis; Johan W Mouton; Juan Luis Rodriquez-Tudela; J Peter Donnelly; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  In vitro activities of four novel triazoles against Scedosporium spp.

Authors:  A J Carrillo; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.

Authors:  Thomas J Walsh; Irja Lutsar; Timothy Driscoll; Bertrand Dupont; Maureen Roden; Parvis Ghahramani; Michael Hodges; Andreas H Groll; John R Perfect
Journal:  Pediatr Infect Dis J       Date:  2002-03       Impact factor: 2.129

Review 6.  Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis.

Authors:  M A Nesky; E C McDougal; J E Peacock
Journal:  Clin Infect Dis       Date:  2000-09-27       Impact factor: 9.079

7.  Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs.

Authors:  Donna M MacCallum; Frank C Odds
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790

8.  Experimental murine model of disseminated Pseudallescheria infection.

Authors:  G M González; R Tijerina; L Najvar; M Rinaldi; I T Yeh; J R Graybill
Journal:  Med Mycol       Date:  2002-06       Impact factor: 4.076

9.  Comparison of the virulence of Scedosporium prolificans strains from different origins in a murine model.

Authors:  M Ortoneda; F J Pastor; E Mayayo; J Guarro
Journal:  J Med Microbiol       Date:  2002-11       Impact factor: 2.472

Review 10.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Authors:  A Espinel-Ingroff; K Boyle; D J Sheehan
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785
View more
  13 in total

1.  Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.

Authors:  Fèlix Gilgado; Carolina Serena; Josep Cano; Josepa Gené; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

2.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.

Authors:  Clara Yustes; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Experimental murine scedosporiosis: histopathology and azole treatment.

Authors:  M Mar Rodríguez; F Javier Pastor; Valentina Salas; Enrique Calvo; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 5.  Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.

Authors:  Joanna M Schaenman; Daniel B DiGiulio; Laurence F Mirels; Nancy M McClenny; Gerald J Berry; Annette W Fothergill; Michael G Rinaldi; Jose G Montoya
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

6.  Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.

Authors:  Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 7.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

8.  Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.

Authors:  M Mar Rodríguez; Carolina Serena; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

9.  Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis.

Authors:  Maria V Castelli; Maria J Buitrago; Leticia Bernal-Martinez; Alicia Gomez-Lopez; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2008-08-06       Impact factor: 5.948

10.  Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.

Authors:  Peter Troke; Koldo Aguirrebengoa; Carmen Arteaga; David Ellis; Christopher H Heath; Irja Lutsar; Montserrat Rovira; Quoc Nguyen; Monica Slavin; Sharon C A Chen
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.